Carmoterol

Chemical compound
  • None
Legal statusLegal status
  • Development terminated
Identifiers
  • 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one
CAS Number
  • 147568-66-9
PubChem CID
  • 63952
IUPHAR/BPS
  • 7582
ChemSpider
  • 57545 checkY
UNII
  • 9810NUL4D1
ChEMBL
  • ChEMBL1094785 checkY
CompTox Dashboard (EPA)
  • DTXSID201046374 Edit this at Wikidata
Chemical and physical dataFormulaC21H24N2O4Molar mass368.433 g·mol−13D model (JSmol)
  • Interactive image
  • C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O
InChI
  • InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1
  • Key:IHOXNOQMRZISPV-YJYMSZOUSA-N

Carmoterol (INN;[1] development codes TA-2005 and CHF-4226) is a non-catechol[2] experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA)[2][3] that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.[4]

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg.[2] The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. It is over 100 times more selective for bronchial muscle than myocardial tissue.[5]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). WHO Drug Information. 19 (1): 74. 2005. Retrieved 25 March 2016.
  2. ^ a b c Mario C, Monica K (2008). "27. Bronchodilators: Beta2-Agonists and Anticholingercs". Clinical Asthma. Philadelphia, PA: Mosby / Elsevier Health Sciences. ISBN 978-0-323-04289-5.
  3. ^ Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.
  4. ^ "Chiesi: Annual Report 2010" (PDF). Chiesi Farmaceutici S.p.A. p. 20. Retrieved 27 March 2016.
  5. ^ Donohue JF (2006). "New Options in COPD Therapy". Medscape. Retrieved 27 March 2016.
  • v
  • t
  • e
Adrenergic receptor modulators
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Dopaminergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
  • v
  • t
  • e
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products
Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e